Randomized Controlled Trial: Improving Medication Adherence with Artificial Intelligence


AllazoHealth and Large Regional Payer Validate Use of Artificial Intelligence in Improving Medication Adherence with Randomized Controlled Study

AllazoHealth has co-published a randomized controlled study with Blue Cross Blue Shield of North Carolina. The study titled, “Improving Medication Adherence by Better Targeting Interventions Using Artificial Intelligence – a Randomized Controlled Trial”, was conducted for the health plan’s Medicare Advantage Part D (MAPD) population of 104,392 patients. The main objective was to improve adherence rates across the three groupings of medication classes that are directly tied to end-of-year Star Ratings and bonus payments: renin angiotensin system antagonists (RASAs), oral anti-diabetics (OADs), and statins.

Download the Study Here